[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368081-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368081-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plaat2-facilitates-the-development-of-pancreatic-cancer-and-serves-as-a-predictor-of-resistance-to-chemotherapy","PLAAT2 facilitates the development of pancreatic cancer and serves as a predictor of resistance to chemotherapy","","Pancreatic cancer remains a highly lethal malignancy with insufficient reliable biomarkers for prognosis and therapy stratification. PLAAT2, an enzyme associated with lipid metabolism, has unclear roles in pancreatic cancer. Analysis of TCGA-PAAD and independent GEO transcriptomic data integrated with clinical annotations evaluated prognosis, biological functions, immune infiltration, mutational patterns, and predicted drug responses. PLAAT2 expression was further verified in paired tissues using IHC and qRT-PCR, while PLAAT2 knockdown assessed effects on proliferation, migration, invasion, and oxaliplatin sensitivity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plaat2-facilitates-the-development-of-pancreatic-cancer-and-serves-as-a-predictor-of-resistance-to-chemotherapy/368081/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plaat2-facilitates-the-development-of-pancreatic-cancer-and-serves-as-a-predictor-of-resistance-to-chemotherapy/368081.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is PLAAT2 and why was it studied in pancreatic cancer?","Question",{"text":63,"@type":64},"PLAAT2 is a lipid-metabolism–linked enzyme. Its role in pancreatic cancer prognosis and therapy response was previously not fully defined, motivating investigation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was PLAAT2 prognostic value and drug resistance assessed?",{"text":68,"@type":64},"Transcriptomic profiles from TCGA-PAAD and independent GEO datasets were analyzed alongside clinical annotations. A PLAAT2-related prognostic signature was built using LASSO–Cox analysis and validated in external GEO cohorts, alongside predicted drug responses.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports PLAAT2’s functional role?",{"text":72,"@type":64},"PLAAT2 expression was confirmed higher in tumor tissues than adjacent non-tumor tissues using immunohistochemistry and quantitative RT-PCR. PLAAT2 silencing reduced proliferation, migration, and invasion in pancreatic cancer cell lines and enhanced oxaliplatin growth-inhibitory effects with reduced IC50 values.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368081,1791167801,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Chen et al. BMC Cancer (2026) 26:125 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-15481-2](https://doi.org/10.1186/s12885-025-15481-2)  \nRESEARCH Open Access  \nPLAAT2 facilitates the development of pancreatic cancer and serves as a predictor of resistance to chemotherapy  \nQiyang Chen 1,3†, Ting Liang2,3†, Chenhao Wu 1,3†, Jingjing Lu3, Xiaohong Li3, Jian Wan 1, Yuhua Lu 1* and Qingsong Guo 1*  \nAbstract  \nBackground Pancreatic cancer (PC) remains one of the deadliest human malignancies, and reliable biomarkers for prognosis and therapeutic stratification are still lacking. PLAAT2 (phospholipase A and acyltransferase 2), an enzyme linked to lipid metabolism, has been implicated in metabolic regulation, but its role in PC is not fully defined. Methods Transcriptomic profiles from TCGA-PAAD and independent GEO datasets, together with the corresponding clinical annotations, were analysed to clarify the prognostic relevance and biological roles of PLAAT2 . Functional enrichment, immune-cell infiltration, mutational profiles and predicted drug responses were analyzed, and a PLAAT2-related prognostic signature was generated by LASSO–Cox analysis and validated in external GEO datasets. In parallel, PLAAT2 expression was examined in paired PC tissues and matched non-cancerous counterparts by immunohistochemistry (IHC) and quantitative RT-PCR. The effects of PLAAT2 silencing on proliferation, migration, invasion and oxaliplatin sensitivity were evaluated in MiaPaCa-2 and CFPAC-1 cells.  \nResults PLAAT2 levels were substantially higher in PC specimens, and tumours with high PLAAT2 expression tended to exhibit more advanced grade and stage together with poorer survival. High PLAAT2 expression was enriched in lipid-metabolic pathways and linked to an immune-dysregulated microenvironment characterized by reduced CD8⁺ T-cell infiltration and increased macrophages. The PLAAT2-high cohort also exhibited a higher frequency of somatic mutations, particularly in KRAS andTP53 . An 11-gene PLAAT2-related signature stratified patients into distinct risk groups; high-risk patients showed significantly worse survival and lower predicted sensitivity to irinotecan, olapariband oxaliplatin, and these findings were consistently validated in independent GEO cohorts. In an institutional cohort of 15 paired clinical samples, IHC and qRT-PCR confirmed higher PLAAT2 expression in tumor tissues than in adjacent non-tumor tissues. Functionally, PLAAT2 knockdown in MiaPaCa-2 and CFPAC-1 cells suppressed cell growth,  \n†Qiyang Chen, Ting Liang and Chenhao Wu contributed equally to this work.  \n*Correspondence: Yuhua Lu [lyh76@126.com](lyh76@126.com)[ ](lyh76@126.com)Qingsong Guo [ntgglj@163.com](ntgglj@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nChen et al. BMC Cancer (2026) 26:125 Page 2 of 18  \nmigration and invasion and significantly enhanced the growth-i","cbCaivFvQoUgY00E","https://ap.wps.com/l/cbCaivFvQoUgY00E","pdf",4803007,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What is PLAAT2 and why was it studied in pancreatic cancer?\",\"answer\":\"PLAAT2 is a lipid-metabolism–linked enzyme. Its role in pancreatic cancer prognosis and therapy response was previously not fully defined, motivating investigation.\"},{\"question\":\"How was PLAAT2 prognostic value and drug resistance assessed?\",\"answer\":\"Transcriptomic profiles from TCGA-PAAD and independent GEO datasets were analyzed alongside clinical annotations. A PLAAT2-related prognostic signature was built using LASSO–Cox analysis and validated in external GEO cohorts, alongside predicted drug responses.\"},{\"question\":\"What experimental evidence supports PLAAT2’s functional role?\",\"answer\":\"PLAAT2 expression was confirmed higher in tumor tissues than adjacent non-tumor tissues using immunohistochemistry and quantitative RT-PCR. PLAAT2 silencing reduced proliferation, migration, and invasion in pancreatic cancer cell lines and enhanced oxaliplatin growth-inhibitory effects with reduced IC50 values.\"}]","PLAAT2 facilitates the development of pancreatic cancer and serves as a predictor of resistance to chemotherapy | PDF",1790174884,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d08cbd7b6bb8d628b8c000a064c36035.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c24dbe9a957038c80d500466013b64d1.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/abf02c530ef1711c9d26a8aa5a1251ad.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91e24c275f703af7ce3f3f527e948b5c.webp",980,1306]